688553 汇宇制药
已收盘 07-30 15:00:00
资讯
新帖
简况
汇宇制药(688553.SH):注射用HY0001a I期临床试验首例受试者给药
智通财经 · 08:42
汇宇制药(688553.SH):注射用HY0001a I期临床试验首例受试者给药
汇宇制药-W涨5.24% 资金博弈与政策扰动共振引发波动
智选洞察 · 07-29 03:13
汇宇制药-W涨5.24% 资金博弈与政策扰动共振引发波动
每周股票复盘:汇宇制药(688553)股东黄干益减持计划到期未减持
证券之星 · 07-26
每周股票复盘:汇宇制药(688553)股东黄干益减持计划到期未减持
汇宇制药(688553.SH)子公司产品获得境外上市许可
智通财经 · 07-25
汇宇制药(688553.SH)子公司产品获得境外上市许可
汇宇制药:股东黄干益未减持公司股份
格隆汇 · 07-25
汇宇制药:股东黄干益未减持公司股份
汇宇制药-W涨5.23% 创新药研发进展及国际化布局提振股价
智选洞察 · 07-17
汇宇制药-W涨5.23% 创新药研发进展及国际化布局提振股价
汇宇制药新提交1件商标注册申请
证券之星 · 07-15
汇宇制药新提交1件商标注册申请
汇宇制药:“高端绿色药物产业延链项目”予以结项
格隆汇资讯 · 07-15
汇宇制药:“高端绿色药物产业延链项目”予以结项
7月14日汇宇制药现2笔大宗交易 机构净买入2000.13万元
证券之星 · 07-14
7月14日汇宇制药现2笔大宗交易 机构净买入2000.13万元
汇宇制药-W股价涨5.00% 创新药研发推进与政策风险角力
智选洞察 · 07-10
汇宇制药-W股价涨5.00% 创新药研发推进与政策风险角力
汇宇制药-W股价涨5.14% 创新药研发进展与资金博弈共振
智选洞察 · 07-09
汇宇制药-W股价涨5.14% 创新药研发进展与资金博弈共振
汇宇制药-W涨5.59% 创新药推进与资金博弈共振
智选洞察 · 07-08
汇宇制药-W涨5.59% 创新药推进与资金博弈共振
聚焦川渝板块丨汇宇制药31.88%列川股周涨幅第一
上游新闻 · 07-06
聚焦川渝板块丨汇宇制药31.88%列川股周涨幅第一
每周股票复盘:汇宇制药(688553)产品获多国上市许可,新药临床试验获批
证券之星 · 07-05
每周股票复盘:汇宇制药(688553)产品获多国上市许可,新药临床试验获批
7月4日汇宇制药(688553)龙虎榜数据:机构净卖出1551.77万元
证券之星 · 07-04
7月4日汇宇制药(688553)龙虎榜数据:机构净卖出1551.77万元
汇宇制药-W涨5.16%创近2年新高 创新药管线突破推动估值重构
智选洞察 · 07-04
汇宇制药-W涨5.16%创近2年新高 创新药管线突破推动估值重构
汇宇制药-W上涨5.05% 创新药研发重塑估值逻辑
智选洞察 · 07-03
汇宇制药-W上涨5.05% 创新药研发重塑估值逻辑
汇宇制药-W股价上涨5.10% 创新驱动与市场扩容预期提振估值
智选洞察 · 07-01
汇宇制药-W股价上涨5.10% 创新驱动与市场扩容预期提振估值
汇宇制药:公司产品获得境外上市许可
新浪财经 · 06-30
汇宇制药:公司产品获得境外上市许可
公司动态研究报告:业绩稳健增长,创新药布局加速推进
东方财富 · 06-29
公司动态研究报告:业绩稳健增长,创新药布局加速推进
加载更多
公司概况
公司名称:
四川汇宇制药股份有限公司
所属行业:
医药制造业
上市日期:
2021-10-26
主营业务:
四川汇宇制药股份有限公司主营业务为肿瘤治疗领域药物和复杂注射剂药物的研发、生产和国内外销售。主要产品有原料药、抗肿瘤注射剂、肿瘤辅助用药等。公司荣登“2022年四川省新经济100强企业榜单”;荣获“四川省2022年度科技创新引才引智先进基地”;荣获“2023年中国医药新锐创新力量”;荣获“四川企业技术创新发展能力100强”且名次跃升至第6位;再次斩获“四川企业技术创新发展最具潜力20强企业”;荣获“2023年度科技人才工作先进单位”表彰授牌。
发行价格:
38.87
{"stockData":{"symbol":"688553","market":"SH","secType":"STK","nameCN":"汇宇制药","latestPrice":22.68,"timestamp":1753858800000,"preClose":22.59,"halted":0,"volume":23952891,"delay":0,"changeRate":0.004,"floatShares":344000000,"shares":424000000,"eps":0.5981,"marketStatus":"已收盘","change":0.09,"latestTime":"07-30 15:00:00","open":22.26,"high":24.15,"low":22.05,"amount":553000000,"amplitude":0.093,"askPrice":22.69,"askSize":16,"bidPrice":22.68,"bidSize":309,"shortable":0,"etf":0,"ttmEps":0.5981,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753925400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.59,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":24.85,"lowLimit":20.33,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423600000,"isCdr":false,"pbRate":2.43,"roa":"--","peRate":37.92008,"roe":"--","epsLYR":0.77,"committee":-0.07565,"marketValue":9607000000,"turnoverRate":0.0697,"status":0,"afterMarket":{"amount":0,"volume":0,"close":22.68,"buyVolume":600,"sellVolume":0,"time":1753860838019,"indexStatus":"已收盘 07-30 15:30:00","preClose":22.59},"floatMarketCap":7791000000},"requestUrl":"/m/hq/s/688553","defaultTab":"news","newsList":[{"id":"2555301969","title":"汇宇制药(688553.SH):注射用HY0001a I期临床试验首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2555301969","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555301969?lang=zh_cn&edition=full","pubTime":"2025-07-30 16:42","pubTimestamp":1753864964,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药 发布公告,公司全资子公司四川汇宇海玥医药科技有限公司自主研发的1类生物创新药注射用HY0001a正在开展用于治疗晚期实体瘤的I期临床试验,于近日成功完成首例受试者给药。截至本公告披露日,国内外尚无同靶点产品获批上市。临床前研究表明,HY0001a在多种实体瘤模型中表现出优秀的抗肿瘤效果且安全性良好,具有巨大的临床开发价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1323622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688553","03347","BK1583","BK1576","BK1141"],"gpt_icon":0},{"id":"2555860330","title":"汇宇制药-W涨5.24% 资金博弈与政策扰动共振引发波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2555860330","media":"智选洞察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555860330?lang=zh_cn&edition=full","pubTime":"2025-07-29 11:13","pubTimestamp":1753758811,"startTime":"0","endTime":"0","summary":"汇宇制药-W今日股价大幅上涨,最新价22.11元/股,涨跌幅为5.24%。资金博弈与政策扰动共振引发波动短期净流出主要源于资金面博弈与政策预期扰动。截至7月28日,汇宇制药主力资金连续两日净流出6293.2万元,机构与游资分歧明显。消息面上,股东黄干益6.43%股权司法冻结引发流动性担忧,叠加公司2025年前三季度预亏2562万元的业绩压力,市场避险情绪升温。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729111334a468c298&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729111334a468c298&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2554771112","title":"每周股票复盘:汇宇制药(688553)股东黄干益减持计划到期未减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2554771112","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554771112?lang=zh_cn&edition=full","pubTime":"2025-07-27 02:03","pubTimestamp":1753552993,"startTime":"0","endTime":"0","summary":"截至2025年7月25日收盘,汇宇制药报收于20.73元,较上周的22.35元下跌7.25%。本周,汇宇制药7月22日盘中最高价报23.62元,股价触及近一年最高点。本周关注点公司公告汇总:汇宇制药股东黄干益减持计划到期未减持任何股份公司公告汇总持股5%以上股东减持股份计划时间届满暨减持股份结果公告:截至公告披露,股东黄干益持有汇宇制药股份数量为27,219,439股,占公司总股本的6.426%。黄干益基于自身原因未实施减持计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072700000229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2554752682","title":"汇宇制药(688553.SH)子公司产品获得境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2554752682","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554752682?lang=zh_cn&edition=full","pubTime":"2025-07-25 16:02","pubTimestamp":1753430551,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司子公司Seacross Pharma(Europe) Ltd.近期收到德国国家药品和保健品安全局和沙特阿拉伯健康产品监管局分别核准签发的公司产品唑来磷酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液和注射用盐酸苯达莫司汀的上市许可。公司研发的唑来膦酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液、注射用盐酸苯达莫司汀分别获得德国、沙特阿拉伯的上市许可,有利于公司在国际市场产品管线的丰富,提升市场的品牌形象,持续拓展国际业务的广度和深度,为国际市场的可持续发展进一步夯实了基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321948.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"汇宇制药(688553.SH)子公司产品获得境外上市许可","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2554769098","title":"汇宇制药:股东黄干益未减持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2554769098","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554769098?lang=zh_cn&edition=full","pubTime":"2025-07-25 15:45","pubTimestamp":1753429550,"startTime":"0","endTime":"0","summary":"格隆汇7月25日丨汇宇制药(688553.SH)公布,公司于近日收到股东黄干益出具的《关于减持计划时间届满暨减持股份结果的告知函》,股东黄干益本次减持计划时间届满,在本次减持计划期间内,股东黄干益未减持公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725154601971dd497&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725154601971dd497&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2552105511","title":"汇宇制药-W涨5.23% 创新药研发进展及国际化布局提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=2552105511","media":"智选洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552105511?lang=zh_cn&edition=full","pubTime":"2025-07-17 13:29","pubTimestamp":1752730178,"startTime":"0","endTime":"0","summary":"汇宇制药-W今日股价明显拉升,截至13点28分,报20.32元/股,涨幅达5.23%,成功站上20元整数关口。多重扰动因素触发股价剧烈波动汇宇制药-W近期的股价波动与资金面及消息面共振密切相关。截至7月16日,主力资金连续四日累计净流出超1.6亿元,直接诱因包括股东黄干益6.43%股权遭司法冻结引发的流动性担忧。2024年海外收入同比激增97.12%,覆盖68国市场,双靶点新药HY-0002a进入I/II期临床,生物药HY-0007完成首例受试者给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717132942a6aef217&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717132942a6aef217&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688553","BK0239"],"gpt_icon":0},{"id":"2551192037","title":"汇宇制药新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2551192037","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551192037?lang=zh_cn&edition=full","pubTime":"2025-07-16 05:18","pubTimestamp":1752614309,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示,近日四川汇宇制药股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来四川汇宇制药股份有限公司新申请注册商标31件,截止目前公司共持有注册商标648件,另有128件商标尚在注册申请中。通过天眼查大数据分析,四川汇宇制药股份有限公司共对外投资了13家企业,参与招投标项目674次;财产线索方面有商标信息452条,专利信息135条,著作权信息2条;此外企业还拥有行政许可109个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600003759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2551315794","title":"汇宇制药:“高端绿色药物产业延链项目”予以结项","url":"https://stock-news.laohu8.com/highlight/detail?id=2551315794","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551315794?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:41","pubTimestamp":1752568862,"startTime":"0","endTime":"0","summary":"格隆汇7月15日丨汇宇制药(688553.SH)公布,公司于2025年7月15日召开第二届董事会第十六次会议和第二届监事会第十六次会议,审议通过了《关于超募资金投资项目结项的议案》,同意对公司超募资金投资项目“高端绿色药物产业延链项目”予以结项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071516412697a6cd0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071516412697a6cd0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2551901430","title":"7月14日汇宇制药现2笔大宗交易 机构净买入2000.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551901430","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551901430?lang=zh_cn&edition=full","pubTime":"2025-07-14 17:20","pubTimestamp":1752484831,"startTime":"0","endTime":"0","summary":"证券之星消息,7月14日汇宇制药发生大宗交易,交易数据如下:近三个月该股共发生5笔大宗交易,合计成交5.45万手,折价成交5笔。该股在过去半年内已有共计3400.65万股限售解禁股上市,占公司总股本的8.03%。截至2025年7月14日收盘,汇宇制药(688553)报收于19.73元,下跌1.69%,换手率4.78%,成交量16.42万手,成交额3.23亿元。该股最近90天内共有2家机构给出评级,买入评级2家。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071400024797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2550869360","title":"汇宇制药-W股价涨5.00% 创新药研发推进与政策风险角力","url":"https://stock-news.laohu8.com/highlight/detail?id=2550869360","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550869360?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:00","pubTimestamp":1752112814,"startTime":"0","endTime":"0","summary":"汇宇制药-W今日股价大幅上涨,截至09点59分,最新价为21.02元/股,涨幅达5.00%。多重因素交织引发股价波动汇宇制药-W近期股价波动显著,截至7月9日,主力资金单日净流入7827.9万元,但前一周累计净流出达6798万元,显示资金博弈加剧。创新药研发与政策风险角力公司长期价值锚定于创新药管线突破及全球化进程。机构预测2025年营收目标12.05亿元,若临床数据超预期,动态市盈率有望上修,但业绩真空期或延续股价高波动特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710100016a6a07cfd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710100016a6a07cfd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159992","688553"],"gpt_icon":0},{"id":"2550150340","title":"汇宇制药-W股价涨5.14% 创新药研发进展与资金博弈共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2550150340","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550150340?lang=zh_cn&edition=full","pubTime":"2025-07-09 09:59","pubTimestamp":1752026344,"startTime":"0","endTime":"0","summary":"汇宇制药-W今日股价大幅上涨,截至09点58分,报20.45元/股,突破20元整数关口,涨幅达5.14%。资金博弈与事件冲击共振汇宇制药-W近期股价波动显著,截至7月7日,主力资金单日净流出3070万元,而前一周累计净流入1.78亿元。此外,6月26日医药生物板块下跌0.92%拖累市场情绪,叠加游资与机构资金分歧,7月4日龙虎榜显示游资席位中信证券上海分公司等大额买入,但次日机构反向抛售,资金博弈白热化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709095914a43f2098&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709095914a43f2098&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","BK0239","688553"],"gpt_icon":0},{"id":"2549567704","title":"汇宇制药-W涨5.59% 创新药推进与资金博弈共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2549567704","media":"智选洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549567704?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:35","pubTimestamp":1751938503,"startTime":"0","endTime":"0","summary":"汇宇制药-W今日股价大幅上涨,截至09点34分,最新价为21.16元/股,涨幅达5.59%。资金面与消息面共振引发股价震荡汇宇制药-W近一个月股价波动显著,截至7月7日,主力资金单日净流出3070万元,前一周累计净流入1.78亿元。此外,7月4日公司因单日涨幅18.79%登上龙虎榜,游资席位中信证券上海分公司等席位大额买入,但次日部分机构席位反向抛售,显示资金分歧加剧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708093640a43cd6cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708093640a43cd6cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239","159992"],"gpt_icon":0},{"id":"2549378171","title":"聚焦川渝板块丨汇宇制药31.88%列川股周涨幅第一","url":"https://stock-news.laohu8.com/highlight/detail?id=2549378171","media":"上游新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549378171?lang=zh_cn&edition=full","pubTime":"2025-07-06 20:49","pubTimestamp":1751806159,"startTime":"0","endTime":"0","summary":"汇宇制药、通威股份、融发核电分别以涨幅31.88%、17.32%、17.02%,列川股周涨幅前三强。汇宇制药以31.88%列川股周涨幅第一7月4日,汇宇制药上涨18.79%,以20.93元报收,换手率14.20%,成交量48.77万手,成交额9.52亿元,总市值88.66亿元,周涨幅31.88%,居第一,今年以来涨幅累计42.03%。现总股本4.24亿股。2025年一季度,公司实现营业总收入9.63亿元,同比增长19.92%;归母净利润为5788.56万元,同比增长38.53%;扣非后归母净利润为5197.12万元,同比增长43.16%;基本每股收益0.45元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507062146389538790d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507062146389538790d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2549344534","title":"每周股票复盘:汇宇制药(688553)产品获多国上市许可,新药临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2549344534","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549344534?lang=zh_cn&edition=full","pubTime":"2025-07-06 01:21","pubTimestamp":1751736069,"startTime":"0","endTime":"0","summary":"截至2025年7月4日收盘,汇宇制药报收于20.93元,较上周的15.87元上涨31.88%。本周关注点交易信息汇总:汇宇制药因收盘价格涨幅达15%首次上榜龙虎榜。公司公告汇总:汇宇制药子公司产品注射用替考拉宁获得意大利和荷兰上市许可;汇宇制药注射用HY05350获得药物临床试验批准通知书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600000083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK1576","BK1583","BK0239","688553","03347"],"gpt_icon":0},{"id":"2548536487","title":"7月4日汇宇制药(688553)龙虎榜数据:机构净卖出1551.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548536487","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548536487?lang=zh_cn&edition=full","pubTime":"2025-07-04 17:15","pubTimestamp":1751620523,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2025年7月4日公布的交易公开信息显示,汇宇制药因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年7月4日收盘,汇宇制药报收于20.93元,上涨18.79%,换手率14.2%,成交量48.77万手,成交额9.52亿元。从龙虎榜公布的当日买卖数据来看,机构合计净卖出1551.77万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400027266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2548353954","title":"汇宇制药-W涨5.16%创近2年新高 创新药管线突破推动估值重构","url":"https://stock-news.laohu8.com/highlight/detail?id=2548353954","media":"智选洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548353954?lang=zh_cn&edition=full","pubTime":"2025-07-04 11:27","pubTimestamp":1751599676,"startTime":"0","endTime":"0","summary":"汇宇制药-W今日股价明显上涨,截至11点27分,最新价为18.53元/股,涨幅达5.16%,创近2年新高。多重事件扰动引发资金博弈汇宇制药-W股价近期波动显著,截至7月3日,主力资金单日净流入6383.4万元,较前一日流出1174.4万元呈现反转。创新药管线突破决定估值重构空间长期走势核心取决于创新药研发及全球化进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704112800a4ce90c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704112800a4ce90c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553","159992"],"gpt_icon":0},{"id":"2548404168","title":"汇宇制药-W上涨5.05% 创新药研发重塑估值逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2548404168","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548404168?lang=zh_cn&edition=full","pubTime":"2025-07-03 10:03","pubTimestamp":1751508223,"startTime":"0","endTime":"0","summary":"汇宇制药-W今日股价表现强势,截至10点03分,最新价报17.07元/股,上涨5.05%。多重压力下的资金博弈汇宇制药-W近期股价波动加剧,截至7月1日,主力资金累计净流出超600万元,资金面扰动与事件性冲击形成共振。股东黄干益6.426%股份因借贷纠纷被司法冻结,叠加2025年一季度营收同比下滑1.46%、净利润亏损扩大至2562万元,引发机构投资者对流动性的担忧。创新药研发重塑估值逻辑企业长期价值仍取决于创新管线突破与国际化进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703100352a72b9f87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703100352a72b9f87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239","159992"],"gpt_icon":0},{"id":"2548002442","title":"汇宇制药-W股价上涨5.10% 创新驱动与市场扩容预期提振估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2548002442","media":"智选洞察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548002442?lang=zh_cn&edition=full","pubTime":"2025-07-01 13:36","pubTimestamp":1751348198,"startTime":"0","endTime":"0","summary":"汇宇制药-W今日股价大幅上涨,截至13点36分,最新价为17.12元/股,涨幅达5.10%。多重因素共振下的股价波动股东股权冻结与业绩承压形成短期扰动。截至6月30日,汇宇制药主力资金累计净流出超600万元,直接诱因来自股东黄干益持有的6.426%股份因借贷纠纷被司法冻结,引发机构资金避险需求。创新驱动与市场扩容的价值重估研发突破与国际化战略构成长期支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701133640a727a46d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701133640a727a46d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2547406748","title":"汇宇制药:公司产品获得境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2547406748","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547406748?lang=zh_cn&edition=full","pubTime":"2025-06-30 17:49","pubTimestamp":1751276998,"startTime":"0","endTime":"0","summary":"格隆汇6月30日丨汇宇制药公布,公司子公司Seacross PharmaLtd.近期收到意大利国家药品和保健品安全局和荷兰健康产品监管局分别核准签发的公司产品注射用替考拉宁的上市许可。公司注射用替考拉宁研发成功后已进行了多国注册申报,分别已在中国、英国、法国、爱尔兰、葡萄牙、意大利、荷兰7个国家获得上市许可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630175238a725d670&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630175238a725d670&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2547138707","title":"公司动态研究报告:业绩稳健增长,创新药布局加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2547138707","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547138707?lang=zh_cn&edition=full","pubTime":"2025-06-29 11:00","pubTimestamp":1751166047,"startTime":"0","endTime":"0","summary":"公司坚持以研发驱动为战略,专注肿瘤创新药和优质仿制药的研发和销售。创新药布局加速推进,三大项目取得阶段性突破公司在创新药领域持续推进研发布局,2024年以来多个项目取得重要进展。截至2024年报,公司在研创新药项目共14个,创新管线布局实现突破。公司新药布局推进顺利,看好后续新药管线持续深化,首次覆盖,给予“买入”投资评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629110051952fcb97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250629110051952fcb97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553","159992"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753894251092,"stockEarnings":[{"period":"1week","weight":0.0544},{"period":"1month","weight":0.3923},{"period":"3month","weight":0.6715},{"period":"6month","weight":0.6113},{"period":"1year","weight":1.0089},{"period":"ytd","weight":0.5318}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0497},{"period":"3month","weight":0.1027},{"period":"6month","weight":0.1123},{"period":"1year","weight":0.2558},{"period":"ytd","weight":0.0788}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川汇宇制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18434人(较上一季度增加4.80%)","perCapita":"18636股","listingDate":"2021-10-26","address":"四川省内江市市中区汉阳路333号3幢","registeredCapital":"42360万元","survey":" 四川汇宇制药股份有限公司主营业务为肿瘤治疗领域药物和复杂注射剂药物的研发、生产和国内外销售。主要产品有原料药、抗肿瘤注射剂、肿瘤辅助用药等。公司荣登“2022年四川省新经济100强企业榜单”;荣获“四川省2022年度科技创新引才引智先进基地”;荣获“2023年中国医药新锐创新力量”;荣获“四川企业技术创新发展能力100强”且名次跃升至第6位;再次斩获“四川企业技术创新发展最具潜力20强企业”;荣获“2023年度科技人才工作先进单位”表彰授牌。","listedPrice":38.87},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汇宇制药,688553,汇宇制药股票,汇宇制药股票老虎,汇宇制药股票老虎国际,汇宇制药行情,汇宇制药股票行情,汇宇制药股价,汇宇制药股市,汇宇制药股票价格,汇宇制药股票交易,汇宇制药股票购买,汇宇制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}